Our Pipeline

WE ARE DEDICATED TO ADVANCING A NOVEL CLASS OF CONDITIONALLY-ACTIVATED PROINFLAMMATORY IMMUNE MODULATORS INTO CLINICAL DEVELOPMENT

CANDIDATE	Discovery	IND-Enabling	Phase 1	Phase 2
WTX-124
WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-2 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in multiple tumor types. WTX-124 is designed to include maintenance of full IL-2 potency, high affinity blockade of IL2 - IL2Rβ/IL2Rγ interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation. We are currently enrolling patients in a first-in-human, Phase 1/1b, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced solid tumors. Expansion arms in select indications are open for enrollment. For more information on this study, visit clinicaltrials.gov (Identifier NCT05479812).
WTX-330
WTX-330 is a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-12 therapy and maximize clinical benefit when administered as monotherapy in refractory and/or immunologically unresponsive tumors. WTX-330 is designed to include high affinity blockade of IL-12 – IL-12R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation. A Phase 1/2 dose- and regimen-finding clinical trial, designed to optimize WTX-330 exposure in the tumor microenvironment and explore activity in selected indications, is expected to begin enrolling in the first quarter of 2025.
WTX-712
WTX-712 is a systemically delivered, conditionally activated Interleukin-21 (IL-21) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-21 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors. In preclinical studies, WTX-712 treatment and subsequent release of IL-21 in the tumor leads to an anti-tumor phenotype through increased immune infiltration, improved CD8+ T cells polyfunctionality, increased GZMB secretion, and the transition of macrophages towards a M1-like (non-suppressive) phenotype. Available for partnering.
WTX-518
WTX-518 is a systemically delivered, conditionally activated Interleukin-18 (IL-18) INDUKINE^TM molecule that is being developed to maximize the potential clinical benefit of IL-18 when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors. Available for partnering.
WTX-921
WTX-921 is a systemically delivered, conditionally activated Interleukin-10 (IL-10) INDUKINE^TM molecule that is being developed for the treatment of inflammatory bowel disease and potentially other inflammatory diseases. Available for partnering.
T Cell Engagers
We are applying our PREDATOR^® protein engineering technology platform for masked and tumor-targeted T cell engager therapies.
PARTNERED PROGRAMS
JZP898 (Formerly WTX-613)
WTX-613 is a systemically delivered, conditionally activated Interferon alpha (IFNα) INDUKINE^TM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IFNα therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors. Our INDUKINE^TM molecule is designed to include high efficiency blockade of IFNα – IFNR interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation. In preclinical studies, WTX-613 exhibits robust anti-tumor activity mediated through stimulation of a type I interferon immune response with excellent pharmacokinetics and tolerability.

Expanded Access Policy:

Expanded access, or compassionate use, is the use of an investigational product prior to regulatory approval and outside of a clinical trial. Werewolf does not currently have an expanded access program or compassionate use program for any of our investigational products. We understand that for people living with cancer, waiting for an approved treatment can be difficult. We believe that devoting ourselves to current and future clinical trials is the best path to meet our goal of providing new treatments to patients with cancer. We encourage any person with cancer interested in gaining access to our investigational therapies to consult their physician(s) regarding the possibility of participating in one of our clinical trials.